ReviewReported positiveLimited evidenceTier 4 · clinical
Drugs · Jun 2026 · regulatory approval summary
Relacorilantepithelial ovarian cancerfallopian tube cancerprimary peritoneal cancerpancreatic cancerprostate cancer Relacorilant is a non-steroidal, selective glucocorticoid receptor antagonist being developed for several solid tumours and Cushing syndrome. The article reports that relacorilant received its first approval in the USA on 25 March 2026 for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after 1-3 prior systemic regimens (at least one including bevacizumab). The article summarizes development milestones leading to this approval.
Studied with: nab-paclitaxel.
Key findings
- Relacorilant is a non-steroidal, selective glucocorticoid receptor II antagonist developed by Corcept Therapeutics.
- Relacorilant received first approval in the USA on 25 March 2026.
- Approval is for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.
- Relacorilant is being developed for various solid tumours including ovarian, fallopian tube, peritoneal, pancreatic and prostate cancers, as well as for Cushing syndrome.
- The article summarizes milestones in the development of relacorilant leading to this approval.
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewReported positiveModerate evidenceTier 4 · clinical
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · Sep 2025 · narrative review
ovarian cancerfallopian tube cancerperitoneal cancerepithelial ovarian cancersovarian germ cell malignanciesovarian stromal malignancies
This is a narrative review updating FIGO staging and summarizing current knowledge on ovarian, fallopian tube, and peritoneal cancers. It describes the 2014 FIGO staging revisions (including subdivisions of Stage IC and IIIC/IIIA) and summarizes genetics, surgical management, chemotherapy, targeted therapies, and aspects of germ cell and stromal ovarian malignancies. The review notes that high-grade serous carcinoma is the most common histology and that no feasible screening strategies currently exist.
Key findings
- FIGO's 2014 staging revision groups ovarian, fallopian tube, and peritoneal cancers in the same system and subdivides Stage IC into IC1 (surgical spill), IC2 (preoperative capsule rupture or tumor on surface), and IC3 (malignant cells in ascites or peritoneal washings).
- Stage IIIC was revised to include a category for spread to retroperitoneal lymph nodes without intraperitoneal dissemination, subdivided into IIIA1(i) (metastasis ≤10 mm) and IIIA1(ii) (metastasis >10 mm); Stage IIIA2 is now defined as microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph nodes.
- Most of these malignancies are high-grade serous carcinomas (HGSCs).
- There are currently no feasible screening strategies for ovarian cancer.
- Diagnosis, treatment, surveillance, and survival have improved due to advances in radiology, pathology, genomics, and molecular biology, and individualized care emphasizes precision surgery to limit morbidity.
- Germline genetic analysis and identification of somatic mutations in tumor tissue provide data informing the use of targeted agents and immunotherapy; the review also covers chemotherapy and management of germ cell and stromal ovarian malignancies.
Limitations: Narrative review with no original patient-level data presented; Abstract does not report review methods, search strategy, or criteria for evidence selection (not identified as a systematic review or meta-analysis); No new primary quantitative data or pooled estimates provided in this abstract.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported positiveStrong evidenceTier 4 · clinicaln = 381
Lancet (London, England) · Jun 2025 · randomized, controlled, open-label phase 3 trial
Relacorilantplatinum-resistant ovarian cancerepithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer This phase 3 randomized trial tested whether adding relacorilant to nab-paclitaxel helped women with platinum-resistant ovarian cancer. The combination improved progression-free survival and also showed a longer overall survival at an interim analysis. Side effects were similar between groups after accounting for nab-paclitaxel exposure, and no new safety signals were seen.
Reported effects: progression-free survival hazard ratio 0.7 [0.54–0.91], p p=0.0076, n=381 · progression-free survival median 6.54 mo [5.55–7.43], n=188 · +3 more
Studied with: nab-paclitaxel.
Key findings
- Progression-free survival was significantly longer with relacorilant plus nab-paclitaxel than with nab-paclitaxel alone.
- An interim overall survival analysis also favored the combination.
- Adverse events were similar across groups when adjusted for nab-paclitaxel exposure; no new safety signals were observed.
Limitations: Open-label design; Overall survival result was based on a planned interim analysis; Trial is ongoing; Funding from the drug manufacturer.
This study evaluated relacorilant as an added anticancer agent in platinum-resistant ovarian cancer.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed